About Panavance Therapeutics

At Panavance, we are focused on giving every patient the best possible chance to live a healthy and cancer-free life. Our clinical-stage drug GP-2250 is bringing new hope to the fight against cancer through truly novel science.

About Panavance Mother Daughter

Who We Are

Panavance Therapeutics Inc. is a clinical-stage pharmaceutical company established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, in order to advance the development of GP-2250, a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them.

With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world. To date, our therapeutic has demonstrated substantial efficacy and safety in extensive preclinical studies, and its early clinical results have been encouraging. Panavance has developed a clear pathway to US registration of GP-2250 for pancreatic cancer.

Why We Exist

We get up every morning with a clear focus on making a significant improvement in clinical outcomes and the lives of cancer patients everywhere. Like the mechanism of our GP-2250, our mission is to disrupt cancer’s energy.

What We Deliver

Our clinical stage asset, GP-2250, has the potential to make a meaningful impact across diverse oncological disease states and therapeutic applications by targeting the primary source of cancer cell energy production with its unique and patent-pending mechanism of action.

Request More Information

Father Son Cancer Survivor

What’s In A Name?
Why We’re Panavance.

Pan Disease Icon

Pan-disease

We believe that our highly tumor cell selective asset may offer a broad benefit across and beyond cancers and in combination with existing treatments.

Pan Therapeutic Icon

Pan-therapeutic

GP-2250 has broad therapeutic potential across stages of disease including before surgery, during surgery, after surgery, and for maintenance therapy in advanced disease.

Pan Creatic Icon

Pan-creatic

Our initial clinical trials are focused on treating pancreatic cancer—a condition with a clear unmet need.

Pan Avance

Pan-avance

We are focused on advancing the effectiveness of cancer treatments and quality of life for patients everywhere.

Meet Leadership Team

Leadership

Meet the Panavance leadership team.

We are led by a highly capable and passionate team that shares wholeheartedly in our mission.

Read More

Our Science Image

Science

Discover our novel mechanism of action.

Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.

Read More